Kimberly Reynolds, Ph.D., concentrates her practice on U.S. and foreign patent prosecution, opinion work, and strategic counseling, primarily in biotechnology and other life sciences. She performs competitive patent analyses, identifies third-party patent risks, and provides patentability and freedom-to-operate opinions. She also has experience opposing and defending patents in U.S. litigation and post-grant proceedings.

Kimberly completed her graduate work at University of Arkansas for Medical Sciences, studying the mechanism of the viral protease and helicase of the hepatitis C virus using biochemical and biophysical techniques and developing nanoparticles to target the viral genome. Her postdoctoral work at Johns Hopkins focused on characterizing the mechanism of a histone acetyl transferase complex that is misregulated in acute myeloid leukemia and epigenetic landscape of transcriptionally active gene bodies using innovative epigenetic and molecular techniques.

Technical areas of Kimberly’s prosecution and opinion work include molecular biology, biochemistry and biochemical pathways, genetics, cellular biology, virology (including methods of treating viral infections and producing viruses), recombinant nucleic acid and protein products (including methods of producing them and use as therapeutics), RNAi, mRNA, lncRNA, chromatin remodeling, array technology, immunology, recombinant antibody screening and engineering, molecular medicine, screening and diagnostic assays and kits, biomarkers (including genomic, proteomic, and metabolic), transgenic plants and animals, cell lines, nanoparticle technology, surgical procedures, and vaccines. Special areas of knowledge include inventions involving gene and genome editing (e.g., CRISPR, TALEN, and ZFN); translational and transcriptional modulation; stem cells and induced pluripotent stem cells; diagnostic, prognostic, and pharmacogenomic biomarkers (e.g., genomic, proteomic, and metabolic biomarkers); next generation sequencing; therapies and diagnostics for autoimmune diseases, mental illnesses, and cancers, including immunotherapies for cancers such as the administration of antibodies or engineered cells, including immune cell therapies expressing chimeric antigen receptors; and molecular design and modeling of drugs.